ECSP11011541A - Antagonistas de la trayectoria hedgehog de ftalazina disustituida - Google Patents
Antagonistas de la trayectoria hedgehog de ftalazina disustituidaInfo
- Publication number
- ECSP11011541A ECSP11011541A EC2011011541A ECSP11011541A ECSP11011541A EC SP11011541 A ECSP11011541 A EC SP11011541A EC 2011011541 A EC2011011541 A EC 2011011541A EC SP11011541 A ECSP11011541 A EC SP11011541A EC SP11011541 A ECSP11011541 A EC SP11011541A
- Authority
- EC
- Ecuador
- Prior art keywords
- antagonists
- hedgehog
- ftalazina
- disttituted
- trajectory
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 2
- 241000027355 Ferocactus setispinus Species 0.000 title 1
- -1 1,4-disubstituted phthalazine Chemical class 0.000 abstract 1
- 241000289669 Erinaceus europaeus Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21862809P | 2009-06-19 | 2009-06-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP11011541A true ECSP11011541A (es) | 2012-01-31 |
Family
ID=42332981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2011011541A ECSP11011541A (es) | 2009-06-19 | 2011-12-16 | Antagonistas de la trayectoria hedgehog de ftalazina disustituida |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US8273742B2 (OSRAM) |
| EP (1) | EP2443104B1 (OSRAM) |
| JP (1) | JP5596139B2 (OSRAM) |
| KR (1) | KR101389165B1 (OSRAM) |
| CN (1) | CN102459233B (OSRAM) |
| AR (1) | AR077014A1 (OSRAM) |
| AU (1) | AU2010260244B2 (OSRAM) |
| BR (1) | BRPI1011601A2 (OSRAM) |
| CA (1) | CA2764542C (OSRAM) |
| CL (1) | CL2011003147A1 (OSRAM) |
| CO (1) | CO6480932A2 (OSRAM) |
| CR (1) | CR20110658A (OSRAM) |
| DK (1) | DK2443104T3 (OSRAM) |
| DO (1) | DOP2011000386A (OSRAM) |
| EA (1) | EA019059B1 (OSRAM) |
| EC (1) | ECSP11011541A (OSRAM) |
| ES (1) | ES2409054T3 (OSRAM) |
| HN (1) | HN2011003139A (OSRAM) |
| HR (1) | HRP20130408T1 (OSRAM) |
| IL (1) | IL216599A (OSRAM) |
| JO (1) | JO2931B1 (OSRAM) |
| MA (1) | MA33363B1 (OSRAM) |
| MX (1) | MX2011014029A (OSRAM) |
| MY (1) | MY156667A (OSRAM) |
| NZ (1) | NZ596882A (OSRAM) |
| PE (1) | PE20121050A1 (OSRAM) |
| PL (1) | PL2443104T3 (OSRAM) |
| PT (1) | PT2443104E (OSRAM) |
| SG (1) | SG177289A1 (OSRAM) |
| SI (1) | SI2443104T1 (OSRAM) |
| TN (1) | TN2011000627A1 (OSRAM) |
| TW (1) | TWI385165B (OSRAM) |
| UA (1) | UA106755C2 (OSRAM) |
| WO (1) | WO2010147917A1 (OSRAM) |
| ZA (1) | ZA201108587B (OSRAM) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2723042A1 (en) * | 2008-04-29 | 2009-11-05 | Eli Lilly And Company | Disubstituted phthalazine hedgehog pathway antagonists |
| HRP20130527T1 (en) * | 2008-11-03 | 2013-07-31 | Eli Lilly And Company | Disubstituted phthalazine hedgehog pathway antagonists |
| HRP20120762T1 (hr) | 2008-11-17 | 2012-10-31 | Eli Lilly And Company | Tetrasupstituirani piridazini kao inhibitori hedgehog puta |
| ES2446307T3 (es) * | 2008-11-17 | 2014-03-07 | Eli Lilly And Company | Piridazinas tetrasustituidas antagonistas de la ruta de Hedgehog |
| AR077014A1 (es) | 2009-06-19 | 2011-07-27 | Lilly Co Eli | Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer |
| EP2688565A1 (en) | 2011-03-23 | 2014-01-29 | Semorex Technologies Ltd. | Treatment of proliferative disorders with a chemiluminescent agent |
| GB201309508D0 (en) * | 2013-05-28 | 2013-07-10 | Redx Pharma Ltd | Compounds |
| GB201311953D0 (en) * | 2013-07-03 | 2013-08-14 | Redx Pharma Ltd | Compounds |
| WO2015073691A1 (en) | 2013-11-14 | 2015-05-21 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for treating cancer by activation of bmp signaling |
| CN105017140B (zh) * | 2014-04-28 | 2017-12-29 | 复旦大学 | 邻氨基苯甲酰胺化合物及其制备方法和用途 |
| GB2528298A (en) * | 2014-07-16 | 2016-01-20 | Redx Pharma Plc | Compounds |
| CN105985319B (zh) * | 2015-02-11 | 2019-02-26 | 复旦大学 | 芳基酞嗪化合物及其制备方法和用途 |
| CN105985320B (zh) * | 2015-02-11 | 2018-10-26 | 复旦大学 | 苄基酞嗪化合物及其制备方法和用途 |
| CN105985321B (zh) * | 2015-02-11 | 2018-10-26 | 复旦大学 | 吡唑酞嗪化合物及其制备方法和用途 |
| JP6796638B2 (ja) | 2015-06-04 | 2020-12-09 | ペレファーム, インク.Pellepharm, Inc. | ヘッジホッグ阻害性化合物の送達のための局所的製剤及びその使用 |
| AU2016271432A1 (en) * | 2015-06-05 | 2017-12-07 | Dana-Farber Cancer Institute, Inc. | Compounds and methods for treating cancer |
| CN120661674A (zh) | 2016-03-15 | 2025-09-19 | 奥莱松基因组股份有限公司 | 用于治疗实体瘤的lsd1抑制剂的组合 |
| CN106279114B (zh) * | 2016-08-04 | 2019-01-29 | 东南大学 | 一种Taladegib的合成方法 |
| US10548908B2 (en) | 2016-09-15 | 2020-02-04 | Nostopharma, LLC | Compositions and methods for preventing and treating heterotopic ossification and pathologic calcification |
| CN106831718B (zh) * | 2016-12-30 | 2019-05-07 | 上海科技大学 | 平滑受体配体及其应用 |
| EP3624798A1 (en) | 2017-05-18 | 2020-03-25 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Methods and pharmaceutical compositions for the treatment of mast cell diseases |
| US20230301950A1 (en) | 2020-06-26 | 2023-09-28 | Raqualia Pharma Inc. | Method for selecting cancer patients for whom combination therapy with retinoid and cancer therapeutic agent is effective, and combination medicament with retinoid and cancer therapeutic agent |
| CA3198661A1 (en) | 2020-10-13 | 2022-04-21 | Endeavor Biomedicines, Inc. | Methods of treating fibrosis |
| US12447148B2 (en) | 2024-03-05 | 2025-10-21 | Endeavor Biomedicines, Inc. | Methods of improving lung function |
| WO2025189041A1 (en) * | 2024-03-07 | 2025-09-12 | Endeavor Biomedicines, Inc. | Methods of treating fibrosis |
| WO2025242197A1 (zh) * | 2024-05-24 | 2025-11-27 | 成都思倍博医药科技有限公司 | 氘代的Hedgehog通路SMO受体抑制剂 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN148482B (OSRAM) | 1977-06-03 | 1981-03-07 | Pfizer | |
| JP4169368B2 (ja) | 1996-01-15 | 2008-10-22 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 脈管形成阻害性ピリダジンアミン |
| EP1067939B1 (en) | 1998-04-09 | 2015-09-16 | The Johns Hopkins University | Use of steroidal alkaloid derivatives as inhibitors of hedgehog protein signaling pathways |
| JP2003501395A (ja) | 1999-06-08 | 2003-01-14 | ローランティス・リミテッド | 治療的使用 |
| NZ530580A (en) * | 2001-07-27 | 2007-02-23 | Curis Inc | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| CA2483311A1 (en) * | 2002-04-22 | 2003-10-30 | Philip A. Beachy | Modulators of hedgehog signaling pathways, compositions and uses related thereto |
| AU2003265853A1 (en) | 2002-08-29 | 2004-03-19 | Curis, Inc. | Hedgehog antagonists, methods and uses related thereto |
| WO2005033288A2 (en) | 2003-09-29 | 2005-04-14 | The Johns Hopkins University | Hedgehog pathway antagonists |
| WO2005080378A1 (ja) | 2004-02-24 | 2005-09-01 | Mitsubishi Pharma Corporation | 縮合ピリダジン誘導体 |
| WO2006004589A2 (en) | 2004-05-08 | 2006-01-12 | Neurogen Corporation | 3-aryl-5,6-disubstituted pyridazines |
| PT1789390E (pt) | 2004-09-02 | 2012-02-08 | Genentech Inc | Inibidores de piridilo da sinalização de hedgehog |
| EP1900731A1 (de) * | 2006-09-07 | 2008-03-19 | Bayer Schering Pharma Aktiengesellschaft | N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren |
| SG182205A1 (en) * | 2007-03-15 | 2012-07-30 | Novartis Ag | Organic compounds and their uses |
| WO2009002469A1 (en) * | 2007-06-25 | 2008-12-31 | Amgen Inc. | Phthalazine compounds, compositions and methods of use |
| AU2008300019A1 (en) | 2007-09-07 | 2009-03-19 | Amgen Inc. | Annelated pyridazines for the treatment of tumors driven by inappropriate hedgehog signalling |
| EP2227456A2 (en) * | 2007-12-13 | 2010-09-15 | Siena Biotech S.p.A. | Hedgehog pathway antagonists and therapeutic applications thereof |
| CA2723042A1 (en) | 2008-04-29 | 2009-11-05 | Eli Lilly And Company | Disubstituted phthalazine hedgehog pathway antagonists |
| US20100041663A1 (en) | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
| AU2009279760B2 (en) * | 2008-08-04 | 2012-07-12 | Amgen Inc. | Aurora kinase modulators and methods of use |
| HRP20130527T1 (en) | 2008-11-03 | 2013-07-31 | Eli Lilly And Company | Disubstituted phthalazine hedgehog pathway antagonists |
| HRP20120762T1 (hr) | 2008-11-17 | 2012-10-31 | Eli Lilly And Company | Tetrasupstituirani piridazini kao inhibitori hedgehog puta |
| ES2446307T3 (es) | 2008-11-17 | 2014-03-07 | Eli Lilly And Company | Piridazinas tetrasustituidas antagonistas de la ruta de Hedgehog |
| AR077014A1 (es) | 2009-06-19 | 2011-07-27 | Lilly Co Eli | Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer |
-
2010
- 2010-06-08 AR ARP100102003A patent/AR077014A1/es active IP Right Grant
- 2010-06-10 JO JO2010188A patent/JO2931B1/en active
- 2010-06-11 TW TW099119158A patent/TWI385165B/zh not_active IP Right Cessation
- 2010-06-15 EA EA201270049A patent/EA019059B1/ru not_active IP Right Cessation
- 2010-06-15 KR KR1020117030157A patent/KR101389165B1/ko not_active Expired - Fee Related
- 2010-06-15 NZ NZ596882A patent/NZ596882A/xx not_active IP Right Cessation
- 2010-06-15 WO PCT/US2010/038568 patent/WO2010147917A1/en not_active Ceased
- 2010-06-15 JP JP2012516178A patent/JP5596139B2/ja active Active
- 2010-06-15 AU AU2010260244A patent/AU2010260244B2/en not_active Ceased
- 2010-06-15 US US12/815,439 patent/US8273742B2/en active Active
- 2010-06-15 HR HRP20130408AT patent/HRP20130408T1/hr unknown
- 2010-06-15 MA MA34455A patent/MA33363B1/fr unknown
- 2010-06-15 DK DK10726756.9T patent/DK2443104T3/da active
- 2010-06-15 CN CN201080027189.3A patent/CN102459233B/zh active Active
- 2010-06-15 SI SI201030200T patent/SI2443104T1/sl unknown
- 2010-06-15 MY MYPI2011006137A patent/MY156667A/en unknown
- 2010-06-15 MX MX2011014029A patent/MX2011014029A/es active IP Right Grant
- 2010-06-15 PE PE2011002119A patent/PE20121050A1/es active IP Right Grant
- 2010-06-15 UA UAA201114996A patent/UA106755C2/uk unknown
- 2010-06-15 PT PT107267569T patent/PT2443104E/pt unknown
- 2010-06-15 EP EP10726756.9A patent/EP2443104B1/en active Active
- 2010-06-15 CA CA2764542A patent/CA2764542C/en not_active Expired - Fee Related
- 2010-06-15 ES ES10726756T patent/ES2409054T3/es active Active
- 2010-06-15 SG SG2011094190A patent/SG177289A1/en unknown
- 2010-06-15 BR BRPI1011601A patent/BRPI1011601A2/pt not_active Application Discontinuation
- 2010-06-15 PL PL10726756T patent/PL2443104T3/pl unknown
-
2011
- 2011-11-22 ZA ZA2011/08587A patent/ZA201108587B/en unknown
- 2011-11-24 IL IL216599A patent/IL216599A/en not_active IP Right Cessation
- 2011-11-29 HN HN2011003139A patent/HN2011003139A/es unknown
- 2011-12-07 TN TNP2011000627A patent/TN2011000627A1/en unknown
- 2011-12-08 CR CR20110658A patent/CR20110658A/es unknown
- 2011-12-13 DO DO2011000386A patent/DOP2011000386A/es unknown
- 2011-12-14 CL CL2011003147A patent/CL2011003147A1/es unknown
- 2011-12-16 EC EC2011011541A patent/ECSP11011541A/es unknown
- 2011-12-22 CO CO11177210A patent/CO6480932A2/es not_active Application Discontinuation
-
2012
- 2012-08-21 US US13/590,481 patent/US9000023B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2011000386A (es) | Antagonistas de la trayectoria hedgehog de ftalazina disustituida | |
| CR11741A (es) | Antagonistas de la trayectoria hedgehog de ftalazina disustituida | |
| CR20110202A (es) | Antagonistas de la via hedgehog de ftalazina disustituida | |
| HN2011002809A (es) | Compuestos de vinil indazolilo | |
| CR20120202A (es) | Métodos y composiciones para tratar cáncer | |
| EA201270619A1 (ru) | Применение бетанехола для лечения ксеростомии | |
| EA200801758A1 (ru) | Лекарственные формы, устойчивые к самовольному изменению | |
| MY153915A (en) | Organic compounds | |
| MX2009006536A (es) | Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales. | |
| EA201101477A1 (ru) | Органические соединения и их применение | |
| CL2009000402A1 (es) | Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras. | |
| EA200971068A1 (ru) | Триазолиламинопиримидиновые соединения | |
| EA201170699A1 (ru) | Тетразамещенные пиридазины в качестве антагонистов пути hedgehog | |
| CL2008000629A1 (es) | Compuestos macrociclicos derivados de 6-aril-4-mercapto-[1.3.5]triazina/[1.3]pirimidin-2-amina; composicion farmaceutica, utiles en el tratamiento del cancer. | |
| EA201170700A1 (ru) | Тетразамещенные пиридазины в качестве антагонистов пути hedgehog | |
| UA110332C2 (en) | Use of 2,3-dihydroxypropyldodecanoate for treatment of seborrhea | |
| EA200971067A1 (ru) | Триазолиламинопиримидиновые соединения | |
| CL2008003931A1 (es) | Compuestos derivados de n-fenil-imidazo-[1,2-a]-piridin-2-carboxamida sustituido; compuestos intermediarios; composicion farmaceutica; utiles en el tratamiento y/o prevencion de enfermedades neurodegenerativas, inflamatorias, epilepsia, osteoporosis, tumores malignos, entre otras. | |
| EA200901613A1 (ru) | Макроциклы и их применение | |
| CL2011002967A1 (es) | Compuestos derivados de 3-oxadiazolil-5-fenil-piperidina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamient y/o profilaxis de trastornos cardiovasculares, tromboembolicos y tumorales. | |
| TN2010000489A1 (en) | Disubstituted phthalazine hedgehog pathway antagonists | |
| CY1114078T1 (el) | Ανταγωνιστες διυποκατεστημενης φθαλαζινης του μονοπατιου hedgehog | |
| TN2010000583A1 (en) | Organic compounds | |
| CY1114071T1 (el) | Ενωσεις βινυλοϊνδαζολυλιου | |
| UA44477U (ru) | Средство для лечения кролей при смешанной эймериозной инвазии |